[ Print version ][ PDF version ]

Summary of Not Recommended Regimens in HCV Treatment
 

Regimens Not Recommended

  • Daily sofosbuvir (400 mg) and weight-based ribavirin for 24  weeks.ƒ
    Rating: Class IIb, Level A

  • PEG-IFN/ribavirin with or without sofosbuvir, simeprevir, telaprevir, or boceprevir.
    Rating: Class IIb, Level A

  • Monotherapy with PEG-IFN, ribavirin, or a direct-acting antiviral.
    Rating: Class III, Level A

 

ƒDue to fewer options in the posttransplant population, sofosbuvir and ribavirin for 24 weeks is recommended in patients with genotype 2 infection.

 

Regimens Not Recommended with Regard to Pregnancy-Related Issues

  • Treatment with ribavirin is Not Recommended during pregnancy or for women who are unable or unwilling to adhere to use of adequate contraception, including those who are receiving ribavirin themselves or are sexual partners of male patients who are receiving ribavirin.
    Rating: Class III, Level C

  • Female patients who have received ribavirin and sexual partners of male patients who have received ribavirin should NOT become pregnant for at least 6 months after stopping ribavirin.
    Rating: Class III, Level B

     

Regimens Not Recommended for Patients with Decompensated Cirrhosis (Moderate or Severe Hepatic Impairment; Child Turcotte Pugh Class B or C)

  • Simeprevir-based regimens.
    Rating: Class III, Level B

  • Paritaprevir-based regimens.
    Rating: Class III, Level B

     

  • Elbasvir/grazoprevir-based regimens.
    Rating: Class III, Level C

     

Regimens Not Recommended for Patients with HCV Infection in the Allograft, Including Those with Compensated Cirrhosis

  • Elbasvir/grazoprevir-based regimens.
    Rating: Class III, Level C

     

Regimens Not Recommended for Patients with Decompensated Cirrhosis Who Have HCV Infection in the Allograft

  • Regimens containing simeprevir.
    Rating: Class III, Level B

  • Fixed-dose combination of paritaprevir, ritonavir, and ombitasvir with or without dasabuvir or ribavirin.
    Rating: Class III, Level B

     

  • Elbasvir/grazoprevir-based regimens.
    Rating: Class III, Level C

Changes made July 6, 2016.